# Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg

> **NCT01073904** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 32 (actual)

## Conditions studied

- Contraceptives, Postcoital

## Interventions

- **DRUG:** Levonorgestrel Emergency Pill (BAY86-5028)
- **DRUG:** Postinor 2

## Key facts

- **NCT ID:** NCT01073904
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073904, "Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01073904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*